<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03024684</url>
  </required_header>
  <id_info>
    <org_study_id>105005</org_study_id>
    <nct_id>NCT03024684</nct_id>
  </id_info>
  <brief_title>Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment</brief_title>
  <acronym>SHOT</acronym>
  <official_title>Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiayi Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tainan Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chi Mei Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiayi Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether statin could prevent recurrence of&#xD;
      hepatocellular carcinoma after curative treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center double-blind randomized placebo-controlled trial. A total of 240&#xD;
      patients with HCC at BCLC stage 0 or A will be enrolled from 8 hospitals in Taiwan. After&#xD;
      complete ablation or hepatic resection of the tumor(s), participants are randomized 1:1 to&#xD;
      receive either atorvastatin 10mg once daily (intervention group) or matched placebo (control&#xD;
      group) for 3 years. During the 3-year period, patients are monitored for recurrence of HCC by&#xD;
      dynamic computed tomography (or magnetic resonance image) every 4 months. They will be&#xD;
      followed up until death, withdrawal from participation, study termination, or 3 years after&#xD;
      the ablative treatment. The primary endpoint is to compare the 3-year cumulative incidence of&#xD;
      recurrent HCC between the intervention group and control counterpart. Secondary endpoints are&#xD;
      occurrence of clinical complications related to hepatic decompensation (including&#xD;
      gastroesophageal variceal bleeding, spontaneous peritonitis, hepatic encephalopathy,&#xD;
      hepatorenal syndrome, and hepatopulmonary syndrome), liver-related mortality, and all-cause&#xD;
      mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart</measure>
    <time_frame>3 years</time_frame>
    <description>Recurrence rate of HCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of clinical complications related to hepatic decompensation</measure>
    <time_frame>3 years</time_frame>
    <description>clinical complications or hepatic decompensation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>HepatoCellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 10mg oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo (sugar pill) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 10mg daily</description>
    <arm_group_label>Statin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo one tablet daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with HCC BCLC stage 0 or A who received curative radiofrequency ablation&#xD;
             or hepatic resection could be eligible.&#xD;
&#xD;
          -  Individuals who had single HCC (size &gt; 5.0 cm) received hepatic resection would be&#xD;
             eligible&#xD;
&#xD;
          -  Individuals with prior history of HCC who had ever received curative ablation or&#xD;
             hepatic resection without any recurrence for more than 2 years could be eligible if&#xD;
             they had a new episode of recurrent HCC which could meet either of the former two&#xD;
             criteria.&#xD;
&#xD;
          -  After 12+/-1 weeks of curative treatment, eligible patients who have no evidence of&#xD;
             local residual or recurrent tumors according to the dynamic CT or MRI could be&#xD;
             enrolled&#xD;
&#xD;
          -  The diagnosis of fresh HCC should be compatible with either pathological report or&#xD;
             meet the criteria of AASLD guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undetermined nature of hepatic tumor&#xD;
&#xD;
          -  HCC with extrahepatic metastasis or major vascular invasion&#xD;
&#xD;
          -  With other malignant disease&#xD;
&#xD;
          -  Child Pugh score &gt;7&#xD;
&#xD;
          -  Previous history of CAD event (angina, unstable angina, acute myocardial infarction)&#xD;
             or ischemic stroke&#xD;
&#xD;
          -  Hyperlipidemia or other indication for statin (according to Taiwan NHI guideline)&#xD;
&#xD;
          -  Advanced CKD (eGFR&lt;30) or ESRD&#xD;
&#xD;
          -  Severe comorbidity with life expectancy &lt; 2 years&#xD;
&#xD;
          -  Allergy to statin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po Yueh Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ditmanson Medical Foundation Chia-Yi Christian Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Po Yueh Chen, Doctor</last_name>
    <phone>+886919860356</phone>
    <email>hdilwy7@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ditmanson Medical Foundation Chiayi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>E-DA Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tainan Municipal Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Yun-Lin Branch</name>
      <address>
        <city>Yunlin</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 15, 2017</study_first_submitted>
  <study_first_submitted_qc>January 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>statin</keyword>
  <keyword>curative ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

